₩8,600.00 ($6.36)

+400.00 (+4.88%)

Weekly Expected Move ±8.2%

₩7186 ₩7893 ₩8600 ₩9307 ₩10014

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 59 · ₩183.8B mcap · 15M float · 0.813% daily turnover

Revenue

$210.4B -4.2% ▼

5Y CAGR: +11.3%

Gross Profit

$67.4B -16.7% ▼

5Y CAGR: +6.6%

Operating Income

-$23.9B -21276.6% ▼

Net Income

-$34.6B -514.5% ▼

EPS (Diluted)

$-1627.95 -420.1% ▼

EBITDA

-$10.7B -223.8% ▼

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$134.2B	$179.7B	$196.3B	$219.7B	$210.4B
YoY Growth	+9.1%	+33.8%	+9.3%	+11.9%	-4.2%
Cost of Revenue	$85.3B	$112.2B	$124.1B	$138.8B	$142.8B
Gross Profit	$49.0B	$67.5B	$72.2B	$80.9B	$67.4B
Gross Margin	36.5%	37.6%	36.8%	36.8%	32.1%
R&D Expenses	$3.0B	$2.9B	$5.6B	$6.4B	$0
SG&A Expenses	$19.7B	$29.2B	$60.0B	$35.5B	$0
Operating Expenses	$48.6B	$63.5B	$65.8B	$80.8B	$91.4B
Operating Income	$400M	$4.0B	$6.5B	$113M	-$23.9B
Operating Margin	0.3%	2.2%	3.3%	0.1%	-11.4%
Interest Expense	$6.2B	$4.3B	$3.5B	$5.1B	$8.8B
Income Before Tax	-$4.8B	$1.1B	$1.4B	-$3.6B	-$37.2B
Tax Expense	$585M	$1.1B	-$240M	$2.0B	-$2.5B
Net Income	-$5.3B	-$28M	$1.7B	-$5.6B	-$34.6B
Net Margin	-4.0%	-0.0%	0.8%	-2.6%	-16.4%
EPS (Diluted)	$-386.63	$-2.03	$115.37	$-313.00	$-1627.95
EBITDA	$6.2B	$10.3B	$10.3B	$8.7B	-$10.7B
Shares Outstanding	14M	14M	14M	18M	21M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$53.3B	$57.8B	$52.3B	$53.8B	$51.2B	$53.1B	$52.5B	$50.6B
Cost of Revenue	$33.8B	$37.3B	$33.8B	$33.1B	$32.7B	$36.0B	$38.0B	$33.9B
Gross Profit	$19.5B	$20.5B	$18.5B	$20.7B	$18.5B	$17.0B	$14.5B	$16.7B
Gross Margin	36.5%	35.5%	35.3%	38.5%	36.1%	31.9%	27.6%	33.0%
R&D Expenses	$1.5B	$2.0B	$2.6B	$1.7B	$2.1B	$1.9B	$1.3B	$1.1B
SG&A Expenses	$19.7B	$10.4B	$23.8B	$23.8B	$9.5B	$13.4B	$11.0B	$21.7B
Operating Expenses	$19.7B	$23.4B	$23.8B	$23.8B	$23.6B	$27.2B	$22.9B	$23.0B
Operating Income	-$240M	-$2.9B	-$5.4B	-$3.1B	-$5.2B	-$10.3B	-$8.4B	-$6.3B
Operating Margin	-0.4%	-4.9%	-10.3%	-5.8%	-10.1%	-19.3%	-16.0%	-12.5%
Interest Expense	-$1.0B	$3.9B	$2.2B	$2.1B	$2.3B	$2.2B	$2.1B	$2.2B
Income Before Tax	$3M	-$5.1B	-$8.5B	-$8.2B	-$7.7B	-$12.7B	-$10.6B	-$8.5B
Tax Expense	$679M	-$1.6B	$538M	-$1.7B	$225M	-$1.6B	$209M	-$806M
Net Income	-$676M	-$3.6B	-$9.1B	-$6.5B	-$7.9B	-$11.1B	-$10.8B	-$7.7B
Net Margin	-1.3%	-6.2%	-17.4%	-12.1%	-15.5%	-20.9%	-20.6%	-15.2%
EPS (Diluted)	$-40.91	$-181.65	$-427.74	$-306.25	$-373.00	$-521.75	$-509.07	$-359.85
EBITDA	$1.1B	$2.0B	-$3.0B	$23.9B	-$2.2B	-$29.5B	-$5.0B	-$2.7B
Shares Outstanding	17M	20M	21M	21M	21M	21M	21M	21M

000520.KS KSC